Adult: In patients who have failed or are intolerant to other approved therapies: As 1% lotion: Apply a thin layer to dry skin and rub in from the neck down to the toes. Wash off after 8-12 hours. Apply only once and do not re-treat. Treatment recommendation may vary among individual products or countries (refer to detailed product guideline).
Topical/Cutaneous Head pediculosis, Pediculosis pubis
Adult: In patients who have failed or are intolerant to other approved therapies: As 1% shampoo: Apply approx 30 mL to dry hair thoroughly and allow to remain in place for 4 minutes. Add small quantities of water to hair until lather forms. Rinse hair thoroughly and dry with a clean towel; comb hair with a fine-tooth comb to remove nits. Amount of shampoo needed will vary depending on the length and density of hair. Max: 60 mL. Do not re-treat. Treatment recommendation may vary among individual products or countries (refer to detailed product guideline).
Hypersensitivity. Uncontrolled seizure disorders, conditions which may increase systemic absorption (e.g. crusted scabies, atopic dermatitis, psoriasis). Premature infants. Lactation.
Patient with history of seizures, previous head trauma, CNS tumour, HIV infection, or other conditions which may increase risk of seizures (e.g. excessive alcohol consumption); other certain skin conditions. Patient weighing <50kg. Hepatic impairment. Infants, children, and elderly. Pregnancy. Not indicated as 1st-line treatment. Avoid using oil treatments, or oil-based hair dressings or conditioners prior to and after application on the affected area.
General disorders and administration site conditions: Pain. Nervous system disorders: Headache, paraesthesia, dizziness. Skin and subcutaneous tissue disorders: Contact dermatitis, rash, alopecia, pruritus, urticaria. Potentially Fatal: Neurotoxicity (e.g. seizures).
Itching may persist even after successful treatment and not necessarily an indication for further treatment.
Monitor for signs and symptoms of neurologic toxicity.
May increase risk of seizures with drugs that may lower the seizure threshold (e.g. antipsychotics, antidepressants, centrally active anticholinesterases, theophylline, isoniazid, meperidine, ciclosporin, mycophenolate mofetil, tacrolimus, penicillins, imipenem, quinolones, chloroquine, pyrimethamine, radiographic contrast agents, methocarbamol).
Description: Lindane is a scabicide and pediculicide. It is directly absorbed by parasites and ova through the exoskeleton and stimulates the nervous system, thereby causing seizures and the eventual death of parasitic arthropods. Pharmacokinetics: Absorption: Slowly and incompletely absorbed through intact skin; increased absorption when applied to weeping or excoriated skin. Distribution: Crosses the placenta and enters breast milk. Metabolism: Metabolised in the liver. Excretion: Via urine and faeces. Elimination half-life: Approx 18 hours.
P03AB02 - lindane ; Belongs to the class of chlorine-containing agents used as ectoparasiticides.
Anon. Lindane. AHFS Clinical Drug Information [online]. Bethesda, MD. American Society of Health-System Pharmacists, Inc. https://www.ahfscdi.com. Accessed 15/02/2021.Anon. Lindane. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 15/02/2021.Buckingham R (ed). Lindane. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 15/02/2021.Lindane Lotion (VersaPharm Incorporated). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 15/02/2021.Lindane Shampoo (VersaPharm Incorporated). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 15/02/2021.Lindane Shampoo, Suspension (Morton Grove Pharmaceuticals, Inc.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 19/02/2021.Scaboma Lotion and Cream (Glenmark Pharmaceuticals Ltd.). MIMS Myanmar. http://www.mims.com/myanmar. Accessed 15/02/2021.